The Investigational New Drug (IND) application for PC-0120, an innovative drug independently developed by PharmaMax Pharmaceuticals, has been accepted by the National Medical Products Administration.
The list of national demonstration objects from 2025 to 2027, aiming to bolster China's position as a leading nation in intellectual property, was released. Among those selected is Jiangsu BioPerfectus Technologies.
The ICGEB China Regional Research Center Offshore Laboratory, a transnational joint research and development platform developed by Taizhou and ICGEB, has begun operating.
Ground has broken on the biosafety and intelligent medical equipment production base project, based on a 100-million-yuan ($14.35-million) investment by Jiangsu Qualia Equipment manufacturing.
Taizhou International Container Terminal in Taizhou city in Jiangsu province saw its container throughput reach 44,822 twenty-foot equivalent units (TEUs) in November, a hefty increase of 42.98 percent.
In the first three quarters, Taizhou's biomedical industry park, also known as China Medical City, recorded invoice sales generated by enterprises above a designated size totaling 18.59 billion yuan ($2.62 billion).
Thirty-seven enterprises operating in the Taizhou Medical High-tech Zone are presenting their innovative products at the 138th edition of the Canton Fair.
A special influenza vaccine independently developed by Ab&B Bio-Tech was recently approved to increase the vaccination population for toddlers aged 6 to 35 months.
